CDC MMWR Vital Signs: Trends in HIV Diagnoses, Risk Behaviors, and Prevention Among Persons Who Inject Drugs — United States
Persons who inject drugs (PWID) are at higher risk for human immunodeficiency virus (HIV) infection, and the U.S. National HIV/AIDS Strategy identifies PWID as a priority population for HIV prevention. Although AIDS diagnoses among PWID have decreased almost 90% since their peak in 1993 and only an estimated 0.3% of the U.S. population has injected drugs in the past 12 months, approximately 9% of HIV infections diagnosed in recent years are among PWID. HIV diagnoses among PWID have decreased over time; however, recent increases in acute hepatitis C virus infections, which are frequently associated with injection drug use, suggest this progress could be negatively affected by increases in opioid and heroin use. Although, decreases in HIV diagnoses among PWID indicate success in HIV prevention, emerging behavioral and demographic trends could reverse this success.
ACOG has released an updated Practice Bulletin, #167, "Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus". This bulletin was developed and updated to educate clinicians about routine HIV screening practices as well as basic women's health screening and care, family planning, and preocnception care for women who are living with HIV. Please note that an ACOG member login is required to access this resource.
In partnership with the Rutgers FXB Center, ACOG is part of a webinar titled "HIV Pre-Exposure Prophylaxis: What Obstetrician-Gynecologists Need to Know" on October 26, 2016, from 1-2:00 p.m. ET. The webinar will include ACOG and CDC guidance on PrEP and clinical scenarios on incorporating PrEP into routine care. Register here.